Telix Pharmaceuticals

TLX.AXPhase 3

Telix Pharmaceuticals is a leader in the radiopharmaceutical space, focused on delivering precision oncology through targeted radiation. The company has achieved commercial success with its prostate cancer imaging agent Illuccix® and is advancing a deep pipeline of theranostic candidates, including its pivotal Phase III therapy program for prostate cancer (ProstACT). With a global operational footprint, including a major manufacturing facility in Belgium, Telix is positioned to scale its innovative platform across multiple high-need cancer indications.

Market Cap

$1.5B

Founded

2015

Focus

AntibodiesBiologicsDiagnostics

TLX.AX · Stock Price

USD 6.15+5.38 (+698.70%)

Historical price data

AI Company Overview

Technology Platform

Targeted radiation theranostics platform using radioactive isotopes attached to targeting agents (antibodies/small molecules) for precise imaging and therapy of cancer cells.

Pipeline Snapshot

21 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Ga-68-PSMA-11	Prostate Cancer	Phase 3
89Zr-TLX250 PET/CT	Clear Cell Renal Cell Carcinoma	Phase 3
68Ga-PSMA-11	Biochemical Recurrence of Malignant Neoplasm of Prostate	Phase 3
177Lu-TLX591 + Enzalutamide + Abiraterone + Docetaxel	Metastatic Castration-resistant Prostate Cancer	Phase 3
Standard of Care	Metastatic Prostate Cancer	Phase 3

Funding History

Total raised: $315M

PIPE$150MUndisclosedJun 15, 2021

Series B$75MBrandon Capital PartnersJun 15, 2018

IPO$75MUndisclosedDec 19, 2017

Series A$15MBrandon Capital PartnersJun 15, 2016

FDA Approved Drugs

GOZELLIXNDAMar 20, 2025

ILLUCCIXNDADec 17, 2021

Opportunities

Telix has significant growth opportunities from the global expansion of its commercial diagnostic Illuccix®, the potential approval and launch of its lead therapeutic TLX591 for prostate cancer, and the expansion of its theranostic platform into new, high-need oncology indications like kidney cancer, brain cancer, and sarcoma.

Its in-house manufacturing scale provides a competitive advantage in a supply-constrained market.

Risk Factors

Key risks include clinical trial failures, regulatory setbacks for late-stage candidates, intense competition from larger pharmaceutical companies, the complexities and costs of manufacturing and distributing short-half-life radiopharmaceuticals, and the challenges of achieving favorable reimbursement in key markets.

Competitive Landscape

Telix faces competition from Novartis (Pluvicto®) and Blue Earth Diagnostics/Bracco (Pylarify®) in prostate cancer, and emerging players in other radiopharma niches. Its differentiation lies in its integrated theranostic pipeline across multiple cancers, proprietary manufacturing infrastructure, and complementary medtech assets like the SENSEI® surgical probe.

Publications

Patents

Pipeline

FDA Approvals